Drug-Eluting Stents
13
1
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
Safety and Efficacy of the Ultimaster Stent
Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
Mono Antiplatelet and Colchicine Therapy
Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database
Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)
In-stent Repair and Vessel Reaction of STEMI Patients With OCT
Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Proper Fractional Flow Reserve Criteria for Intermediate Lesions in the Era of Drug-eluting Stent